Management of Hepatitis C Infection

  • Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 1/9/21 (What's New)

Summary

  • Resistance associated variants have been identified for all DAAs
  • Resistance emerges rapidly with use of DAA monotherapy
  • Cross-resistance occurs within DAA classes
    • Mechanisms of Resistance
      Resistance Associated Variants: Persistence After Treatment Discontinuation and Implications for Retreatment

      Action required

      Keywords: Hepatitis C-Resistance, Hepatitis C-Treatment

      ©2020 Clinical Care Options, LLC. All Rights Reserved.

      The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.